Japan based Nippon Shinyaku Co., LTD. has announced that Janssen Pharmaceutical K.K. and Nippon Shinyaku entered into a new co-promotion agreement about ZYTIGA® (abiraterone acetate) for prostate cancer treatment in Japan.

This new agreement strengthens an already strong collaboration that will drive broader access to ZYTIGA® in Japan and complements the existing co-promotion agreement for ERLEADA® (apalutamide) with Nippon Shinyaku, which has been in place since January 2019.

Nippon Shinyaku will contribute the treatment of prostate cancer through providing appropriate medical information to medical facilities and collection of the information on ZYTIGA® in addition to ERLEADA® in cooperation with Janssen.

Under the agreement, both companies will start co-promoting ZYTIGA® to healthcare professionals in Japan from March 2, 2020, with Janssen retaining marketing authorization for ZYTIGA®